Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: April 1, 2023

Details for Patent: 5,972,882

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $100
Remove trial restrictions

Summary for Patent: 5,972,882
Title: Treatment of polycystic kidney disease using vasopressin V.sub.2 receptor antagonists
Abstract:The present invention is directed to the novel treatment of ARPKD and ADPKD by administering a pharmacologically effective amount of a V.sub.2 receptor antagonist. Orally active V.sub.2 receptor antagonists such as OPC-31260, OPC-41061, SR121463A and VPA-985 are administered alone, or in combination to mammalian PKD subjects to reduce the cAMP generated by the increased expression of AVP-V.sub.2 receptor, AQP2 and AQP3, thereby reducing and/or preventing cyst enlargement.
Inventor(s): Gattone, II; Vincent H. (Overland Park, KS)
Assignee: University of Kansas Medical Center (Kansas City, KS)
Application Number:09/211,396
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 5,972,882

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.